Status:
COMPLETED
Evaluation of 0.05% CsA and 0.1% FK506 Eye Drops in Ocular GVHD Treatment
Lead Sponsor:
Peking University Third Hospital
Conditions:
Graft Versus Host Disease in Eye
Eligibility:
All Genders
4+ years
Phase:
PHASE4
Brief Summary
It is planned to explore the efficacy and safety of local 0.05% cyclosporine eye drops in the treatment of chronic graft-versus-host eye disease. Through the comparative study with 0.1% tacrolimus eye...
Detailed Description
Chronic graft-versus-host disease (GVHD) is a common and serious complication after allogeneic hematopoietic stem cell transplantation. Its clinical presentation is similar to that of an autoimmune di...
Eligibility Criteria
Inclusion
- Diagnosed as chronic ocular GVHD
- Did not receive eye local immunosuppressive therapy
- Non pregnant patients
Exclusion
- Have a history of eye surgery in the past six months
- Suffering from other eye diseases (autoimmune diseases, glaucoma, serious infection, retinopathy, allergy, cataract, eye trauma, etc.)
- Hormones or immunosuppressants were used before enrollment
Key Trial Info
Start Date :
April 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2021
Estimated Enrollment :
89 Patients enrolled
Trial Details
Trial ID
NCT05294666
Start Date
April 1 2020
End Date
July 1 2021
Last Update
March 24 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University Third Hospital
Beijing, Beijing Municipality, China, 100000